S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

Certara (CERT) Stock Price, News & Analysis

$16.37
-0.06 (-0.37%)
(As of 04:23 PM ET)
Compare
Today's Range
$16.04
$16.54
50-Day Range
$12.12
$16.43
52-Week Range
$11.81
$24.96
Volume
578,792 shs
Average Volume
1.00 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.38

Certara MarketRank™ Stock Analysis

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
18.6% Upside
$19.38 Price Target
Short Interest
Healthy
4.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.81mentions of Certara in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$747,870 Sold Last Quarter
Proj. Earnings Growth
3.03%
From $0.33 to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

308th out of 944 stocks

Prepackaged Software Industry

64th out of 189 stocks


CERT stock logo

About Certara Stock (NASDAQ:CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Stock Price History

CERT Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Certara (NASDAQ:CERT) Now Covered by KeyCorp
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Q3 2023 Certara Inc Earnings Call
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
Certara Reports Third Quarter 2023 Financial Results
Circling Back On Certara
Robert W. Baird Reaffirms Their Hold Rating on Certara (CERT)
Certara Inc.
What Is Certara, Inc.'s (NASDAQ:CERT) Share Price Doing?
See More Headlines
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
1,204
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.38
High Stock Price Target
$24.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$14.73 million
Pretax Margin
-11.06%

Debt

Sales & Book Value

Annual Sales
$352.96 million
Cash Flow
$0.66 per share
Book Value
$6.76 per share

Miscellaneous

Free Float
155,689,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
1.57
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. William F. Feehery Ph.D. (Age 52)
    CEO & Director
    Comp: $1.35M
  • Mr. Leif E. Pedersen (Age 58)
    President & Chief Commercial Officer
    Comp: $625.53k
  • Dr. Robert P. Aspbury Ph.D. (Age 51)
    President of Certara Scientific Software
    Comp: $518.09k
  • Dr. Patrick F. Smith Pharm.D. (Age 52)
    President of Drug Development Solutions
    Comp: $621.58k
  • Mr. John E. Gallagher III (Age 50)
    Chief Financial Officer
  • Mr. Max Kanevsky
    Chief Technology Officer
  • Prof. Amin Rostami PharmD
    Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. TraynorMr. Richard M. Traynor (Age 51)
    Senior VP, General Counsel & Secretary
  • Mr. Ron DiSantis
    Senior Vice President of Corporate Development
  • Ms. Sheila Rocchio MBA
    Chief Marketing Officer














CERT Stock Analysis - Frequently Asked Questions

Should I buy or sell Certara stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings
or view top-rated stocks.

What is Certara's stock price target for 2024?

10 equities research analysts have issued 12-month price objectives for Certara's stock. Their CERT share price targets range from $16.00 to $24.00. On average, they expect the company's stock price to reach $19.38 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price.
View analysts price targets for CERT
or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2023?

Certara's stock was trading at $16.07 at the beginning of 2023. Since then, CERT stock has increased by 1.7% and is now trading at $16.34.
View the best growth stocks for 2023 here
.

Are investors shorting Certara?

Certara saw a decline in short interest in November. As of November 15th, there was short interest totaling 4,690,000 shares, a decline of 11.0% from the October 31st total of 5,270,000 shares. Based on an average trading volume of 677,600 shares, the short-interest ratio is currently 6.9 days. Currently, 4.3% of the shares of the company are sold short.
View Certara's Short Interest
.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CERT earnings forecast
.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) released its earnings results on Wednesday, November, 8th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company earned $85.58 million during the quarter, compared to analysts' expectations of $85.96 million. Certara had a negative net margin of 9.56% and a positive trailing twelve-month return on equity of 5.38%.

What guidance has Certara issued on next quarter's earnings?

Certara updated its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $0.44-0.48 for the period, compared to the consensus earnings per share estimate of $0.45. The company issued revenue guidance of $345-360 million, compared to the consensus revenue estimate of $353.75 million.

When did Certara IPO?

(CERT) raised $500 million in an IPO on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Who are Certara's major shareholders?

Certara's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.75%), William Blair Investment Management LLC (4.48%), Clearbridge Investments LLC (2.58%), JPMorgan Chase & Co. (2.44%), Riverbridge Partners LLC (1.65%) and Massachusetts Financial Services Co. MA (1.32%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends
.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERT) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -